Endocrinology

The reprioritization comes as the SIG-001 program remains on clinical hold after scarred and inviable cell spheres were observed in a treated patient.

The patient’s daily insulin requirement went from 34 units a day at baseline to 2.9 units a day 90 days after treatment.

An interim analysis has met prespecified safety and efficacy checkpoints.

Both Vertex and Arbor are adding to their list of gene and cell therapy partnerships with the announcement.

Study examining the role of IL-17A in patients with diabetes.

Selected abstracts from the American Diabetes Association's 80th Scientific Sessions discuss when to add injectable therapy, how patients who switched to semaglutide lost more weight and gained glycemic control, and offered results from an early-phase study on a monoclonal antibody that may preserve B-cell function.

A biomarker for pancreatic precursor cells might give researchers a shortcut to create insulin-producing beta cells that can be transplanted into patients with type 1 diabetes.

The Sanford Project: T-Rex Study has reached its midway point through a Phase II, fast-tracked trial.

Non-viral gene therapy can temporarily reduce painful diabetic neuropathy, according to research from Northwestern Medicine.

A novel treatment method called stem cell educator therapy appears to reverse the effects of type 1 diabetes, researchers at the University of Illinois at Chicago and colleagues in China report.